Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Vir Biotechnology (NASDAQ:VIR) and raises the price target from $27 to $28.
August 02, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Vir Biotechnology and raises the price target from $27 to $28.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for Vir Biotechnology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100